loader2
Login Open ICICI 3-in-1 Account

Cohance Lifesciences Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Cohance Lifesciences Ltd. 13 Aug 2025 17:43 PM

Q1FY26 Quarterly Result Announced for Cohance Lifesciences Ltd.

Pharmaceuticals company Cohance Lifesciences announced Q1FY26 results

  • Company reported revenue of Rs 5,493 million, up 13% YoY growth exceeds 25%.
  • Gross margins expanded to 73.0% from 68.4% in Q1FY25.
  • EBITDA was Rs 1,314 million with a margin of 23.9%.

Vivek Sharma, Executive Chairman, said: "Q1FY26 has been an important start to the year, with progress not just in execution but in strengthening the foundation we have built. Our growing presence in niche modalities like ADCs and oligonucleotides, combined with a deepening global customer base, positions Cohance for accelerated growth. With strengthened leadership and the guidance of our External Advisory Board, we remain committed to becoming a global technology-led CDMO, delivering long-term value for all stakeholders."

Result PDF

Pharmaceuticals company Cohance Lifesciences announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Cohance reported revenue of Rs 8,412 million, up 20% YoY.
  • Adjusted EBITDA stood at Rs 2,632 million for Q4FY25 compared to Rs 2,554 million for Q4FY24 and adjusted EBITDA margin was 31.3%, reflecting continued investments in people and infrastructure across the platform.
  • Adjusted PAT stood at Rs 1,441 million for Q4FY25 compared to Rs 1,721 million for Q4FY24

FY25 Financial Highlights:

  • FY25 revenue grew 9.1% YoY to Rs 26103 million on a combined platform.
  • The company generated free cash flow of Rs 3.61 billion during the year and closed FY25 with Rs 2.90 billion in cash and bank balances, despite incurring M&A investments of Rs 8.06 billion.
  • Adjusted EBITDA stood at Rs 8,781 million for FY25 compared to Rs 8,534 million for FY24
  • Adjusted PAT stood at Rs 5,463 million for FY25 compared to Rs 5,739 million for FY24

Vivek Sharma, Executive Chairman, said: “FY25 was a year of strategic transformation as we built a USD 335 million global CDMO platform with differentiated capabilities across modalities. With the merger now behind us, we move forward under the Cohance identity— a technology-led CDMO focused on science, speed, and reliability. We are excited about the road ahead and remain committed to our goal of becoming a USD 1 billion (Rs 85 billion) CDMO by 2030. The foundation is strong, our pipeline is strengthen, and FY26 will be a year of acceleration as we deepen strategic relationships and scale up differentiated platforms like ADCs and Oligos”

Result PDF

Suven Pharmaceuticals declares Q3FY22 result:

  • The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).
  • The Suven Pharma Inc., the WOS of our Company has divested its entire stake (25% amounting to $35.00 Mn) in M/s Rising Pharma Holdings, Inc., USA on 13th Dec,2021 to Raisin Acquisition Co, Inc., one of the investment arms of H.I.G. Capital, a leading global alternative investment firm in USA through structured deal. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of $ 41.555 Mn and a stake valued at $15.803 Mn in Raisin Aggregators L.P. Accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company w.e.f 13th Dec'2021. Hence, the share of profits of associate has not been considered in the consolidated financial statements for the Quarter ended 31st Dec'2021.
  • The Board has declared an interim Dividend of Rs.1.00 per equity share (100% of Face value of Rs.1.00 each) and one-time special dividend of Rs. 2.00 per equity share (200% of Face value of Rs.1.00), totaling to Rs. 3.00 per equity share (300% of Face value of Rs. 3.00 each) for the financial year 2021-22.
  • The Board in its meeting held on 8th February 2022, has given its in-principle approval to evaluate the acquisition opportunity of Caper Pharma Pvt. Ltd., an SEZ unit in Hyderabad engaged in Formulations. The Company will evaluate the proposal subject to financial, tax and legal due diligence to finalize the definitive agreements.
  • The COVID-19 continuous to impact the business and research operations in India and our wholly owned subsidiary, Suven pharma, Inc., USA.

 

 

Result PDF

Highlights:

  • PAT (Standalone) include INR 332.94 Mn, Dividend from Suven Pharma, Inc., USA.
  • The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).
  • The consolidated financials include the results of the wholly owned subsidiary Suven Pharma, Inc., and associate Rising Pharma Holdings, Inc., USA.
  • The COVID-19 continuous to impact the business and research operations in India and our wholly owned subsidiary, Suven pharma, Inc., USA.
  • Apart from the above, the shortage or non-availability of vessels leading to delay in shipments, increase in the transportation and distribution costs and timely non availability of materials with increase in materials cost are impacting our operations and profitability.

Result PDF

Hightlights:

  • The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).
  • The consolidated financials include the results of the wholly owned subsidiary Suven Pharma, Inc., and associate Rising Pharma Holdings, Inc., USA.
  • The Board has allotted the Bonus shares at 1:1 ratio in its Board meeting held on 29 September’ 2020. Accordingly, the number of shares increased from 12,72,82,478 to 25,45,64,956. In order to maintain uniformity and comparability the EPS of previous period have been restated.
  • The COVID-19 continuous to impact the business and research operations in India, like increase in some of the raw material costs, non-availability of vessels leading to delay in shipments and increase in transportation costs. However, there was no major impact on our wholly owned subsidiary, Suven pharma, Inc., USA.

 

 

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app